A team of researchers led by Harvard University scientists has improved the laboratory process of converting stem cells into insulin-producing beta cells from 30 percent to 80 percent.

A team of investigators from Harvard-affiliated Brigham and Women’s Hospital, MIT, and Novo Nordisk has developed a microneedle pill that can deliver an oral formulation of insulin that can be swallowed rather than injected.